After AstraZeneca and a former manager-turned-whistleblower each scored partial wins in a retaliation and age discrimination lawsuit, AstraZeneca has nabbed a victory in post-trial motions before the U.S. District Court for the District of Oregon.
In the case of Suzanne Ivie, who sued AstraZeneca alleging the company fired her after she raised concerns about off-label marketing, the Oregon District court has vacated a jury's $2.4 million verdict against the drugmaker.
This summer, a jury in Oregon ruled that AstraZeneca violated the state's whistleblower laws by firing Ivie after she reported alleged marketing misconduct. The jurors, however, rejected claims of age discrimination and didn't hold the company liable for alleged violations of the False Claims Act.
After the verdict, AstraZeneca's lawyers said that Ivie failed to meet the necessary threshold to prove violations of Oregon's whistleblower protection laws. Late last week, United States Magistrate Judge Jolie A. Russo agreed with the company's argument, writing that Ivie "failed to present facts required for the jury to find for plaintiff on the whistleblower protection claim." Judge Russo vacated the $2.4 million verdict against AstraZeneca.
Ivie lived in Utah during the time she worked at AstraZeneca, Judge Russo pointed out. Therefore, she "took a calculated risk" bringing her lawsuit in Oregon rather than Utah, which "has no anti-retaliation or whistleblower protection statute applicable to private-sector employees," the judge wrote.
"Having taken that risk, she must now accept the consequence of having presented no Oregon evidence to prove her Oregon claim," Judge Russo added.
In her suit, Ivie alleged that one of her former bosses at AstraZeneca pushed the team to promote certain medicines for uses that were not FDA-approved. When Ivie refused and raised concerns, a pattern of retaliation emerged, she claimed.
AstraZeneca's lawyer said Ivie was fired for failing to do the work expected of her as a district sales manager, Oregonlive reported. The company also said that the off-label allegations were "unsubstantiated."
Editor's note: This story has been corrected to note that the $2.4 million verdict against AstraZeneca was overturned after the trial in the U.S. District Court for the District of Oregon, not in appeals.